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administration in severe sepsis and
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Abstract
Severe systemic inflammatory response to infection results in severe sepsis and septic shock, which are the leading
causes of death in critically ill patients. Septic shock is characterised by refractory hypotension and is typically managed
by fluid resuscitation and administration of catecholamine vasopressors such as norepinephrine. Vasopressin can also
be administered to raise mean arterial pressure or decrease the norepinephrine dose. Endogenous norepinephrine and
vasopressin are synthesised by the copper-containing enzymes dopamine β-hydroxylase and peptidylglycine
α-amidating monooxygenase, respectively. Both of these enzymes require ascorbate as a cofactor for optimal
activity. Patients with severe sepsis present with hypovitaminosis C, and pre-clinical and clinical studies have
indicated that administration of high-dose ascorbate decreases the levels of pro-inflammatory biomarkers, attenuates
organ dysfunction and improves haemodynamic parameters. It is conceivable that administration of ascorbate to
septic patients with hypovitaminosis C could improve endogenous vasopressor synthesis and thus ameliorate the
requirement for exogenously administered vasopressors. Ascorbate-dependent vasopressor synthesis represents a
currently underexplored biochemical mechanism by which ascorbate could act as an adjuvant therapy for severe
sepsis and septic shock.
Introduction
Sepsis is a potentially life-threatening systemic inflam-
matory response to infection which can result in multi-
system organ dysfunction (severe sepsis) and refractory
hypotension (septic shock) [1]. Sepsis is a complex, het-
erogeneous condition that can be caused by any infec-
tious organism, with Gram-positive infections often
predominating [2]. A majority of septic patients have a
pulmonary source of infection, such as pneumonia,
which results in acute respiratory distress syndrome [1].
Dysfunction of cardiovascular, hepatic, renal and central
nervous systems can also occur in severe sepsis [3]. The
incidence of severe sepsis is increasing, due to an in-
creasingly aging population [4], and is currently the lead-
ing cause of death in critically ill patients, with mortality
rates of 30–50 % [5]. The Surviving Sepsis Campaign
has recommended a number of strategies for the manage-
ment of severe sepsis and septic shock, including fluid re-
suscitation, infection control, and respiratory and central
nervous system support [6] and, despite an increase in in-
cidence, mortality rates appear to be declining [7].
Septic shock is characterised by severe alterations in
the cardiovascular system, including ineffective tissue
oxygenation, inappropriate peripheral vasodilation, myo-
cardial dysfunction and altered blood flow distribution,
resulting in hypotension refractory to intravenous fluid
administration [1, 8]. Septic shock is typically managed
through the administration of catecholamine vasopres-
sors (dopamine, norepinephrine or epinephrine), with
norepinephrine being the preferred vasoconstrictor [9].
Vasopressin is also recommended in the Surviving Sepsis
Campaign guidelines to raise mean arterial pressure to
target or to decrease the norepinephrine dose [6]. The
Vasopressin and Septic Shock Trial (VASST) indicated
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that vasopressin provided equivalent mortality rates to
norepinephrine in patients already receiving vasopres-
sors [10]. Exogenous vasopressor administration to pa-
tients with severe sepsis and septic shock, however, can
result in adverse side effects such as decreased cardiac
output and cardiac arrest, mesenteric ischaemia, skin ne-
crosis, digital ischaemia and hyponatraemia [11].
Recent pre-clinical and clinical studies have indicated
a potential role for ascorbate in ameliorating the patho-
physiology of sepsis [12–14]. Numerous studies of septic
animals administered high-dose ascorbate have shown
improved microvascular changes and survival (reviewed
in [14]). A number of mechanisms have been proposed
for ascorbate’s observed activities in sepsis, but these
have primarily focused on its antioxidant and anti-
inflammatory functions, including its effects on signal
transduction pathways in vascular cells (reviewed in
[13]). In contrast, very little attention has been paid to
ascorbate’s enzyme cofactor activities, particularly its
role in the synthesis of vasopressors [15]. In this review
we present the hypothesis that adjuvant ascorbate could
support endogenous vasopressor synthesis in severe sep-
sis and septic shock through acting as an essential cofac-
tor for the metallo-enzymes involved in the biosynthesis
of vasoactive catecholamines and vasopressin.
Ascorbate requirements in sepsis
Ascorbate is an essential micronutrient with numerous
important enzyme cofactor functions in the body [15, 16],
as well as potent antioxidant properties [17, 18]. Humans
have lost the ability to synthesise ascorbate due to muta-
tions in the gene encoding the terminal biosynthetic en-
zyme, and ascorbate must therefore be obtained regularly
through the diet to prevent hypovitaminosis C and the po-
tentially fatal deficiency disease scurvy. Recommended
dietary intakes for ascorbate are typically in the range of
75–110 mg/day [19, 20]. Enteral or parenteral nutrition
administered to critically ill patients provides ~100 mg/
day ascorbate. However, critically ill patients probably re-
quire significantly higher intakes of ascorbate [21] due to
enhanced metabolic turnover of vitamin C during the se-
vere inflammatory response. It should also be noted that
parenteral rather than enteral nutrition may be required
for optimal ascorbate status in critically ill patients be-
cause intravenously administered ascorbate bypasses the
rate-limiting intestinal uptake of orally administered as-
corbate [22].
In healthy fasting humans, circulating levels of ascor-
bate are typically in the range of 50–70 μmol/l, whereas
levels <23 μmol/l are considered marginally deficient (or
hypovitaminosis C) and levels <11 μmol/l are considered
severely deficient and potentially scorbutic [23]. Several
studies have shown that ascorbate levels are low in crit-
ically ill patients (i.e. <23 μmol/l), including those with
acute respiratory infections [24] and sepsis [12, 25], and
are particularly low (i.e. <11 μmol/l) in patients who
progress to multiple organ failure [26]. In some studies,
ascorbate levels remained lower than those in controls,
despite the patients receiving 100–500 mg/day ascorbate
either enterally or parenterally [27, 28]. Long et al. [27]
demonstrated that up to 3000 mg/day ascorbate was re-
quired to return plasma levels of critically ill patients to
normal (i.e. 68 μmol/l).
Interestingly, in animals that are able to synthesise as-
corbate in their livers, studies have shown increased en-
dogenous synthesis of ascorbate when the animals are
exposed to stress [29, 30]. We have also observed en-
hanced mRNA expression of the ascorbate synthesising
enzyme gulonolactone oxidase in lipopolysaccharide-
treated mice (R. Natarajan, unpublished observations).
Enhanced ascorbate synthesis has also recently been
shown in mice exposed to tumour burden [31]. These
studies suggest an important physiological requirement
for ascorbate in conditions of stress and disease burden.
Other studies have shown up to an eight-fold enhance-
ment in the synthesis of ascorbate in animals exposed
to drugs, including hypnotics (sedatives), analgesics and
muscle relaxants [32, 33], probably as a compensatory
mechanism for enhanced metabolism of ascorbate fol-
lowing drug administration [33]. Therefore, it is con-
ceivable that patients with severe infection in intensive
care may have enhanced ascorbate requirements not only
due to the infectious disease process, but also because of
the administration of sedatives and other drugs.
Ascorbate’s role in vasopressor synthesis
Cases of scurvy, the clinical presentation of severe ascor-
bate deficiency, have been reported in critically ill pa-
tients in intensive care (Table 1) [34–36]. One case
presented with multiple organ dysfunction and the intra-
venous administration of ascorbate resulted in improved
cardiovascular functioning within 24 h, particularly in-
creased arterial pressure, decreased heart rate, normal-
ised central venous pressure and a decreased need for
catecholamines [35]. Another case exhibited typical symp-
toms of scurvy as well as severe orthostatic hypotension
that failed to respond to fluids [36]. The patient’s ascor-
bate levels were undetectable and the orthostatic
hypotension resolved within 24 h of ascorbate replace-
ment. The authors suggested that the pathogenesis of
orthostatic hypotension in the setting of scurvy could re-
sult from impaired catecholamine synthesis. Vasopressin
may also play a role in preventing or minimising
orthostatic hypotension [37], indicating a possible link
between ascorbate deficiency and vasopressin insuffi-
ciency in this case [36]. High-dose intravenous ascor-
bate administration to severely burned patients has
been shown to decrease the resuscitation volume
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required [38] and also to decrease the need for vaso-
pressors in some patients (Table 1) [39].
The recent phase I randomised controlled trial in 24
patients with severe sepsis who were administered
intravenous infusions of ascorbate (0, 50 or 200 mg/kg/
24 h) showed prompt reductions in Sequential Organ
Failure Assessment scores in those receiving ascorbate
[12]. A significant reduction in the pro-inflammatory
biomarkers C-reactive protein and procalcitonin was
also observed, as well as attenuation of thrombomodu-
lin levels, suggesting amelioration of vascular endothe-
lial injury. No adverse safety events were observed in
this study. Previously unpublished data from this trial
indicated an increase in systolic blood pressure and
mean arterial pressure in the group that received
200 mg/kg/24 h ascorbate (Fig. 1a, b). Although these
values did not reach statistical significance, probably
due to low patient numbers, this finding lends support
to our hypothesis that administration of ascorbate
could aid in endogenous vasopressor synthesis.
Ascorbate and catecholamine synthesis
Catecholamine neurotransmitters and hormones (dopa-
mine, norepinephrine and epinephrine) are synthesised
within the sympathetic nervous system and the adrenal
medulla (an organ with a very high ability to store vitamin
C). Catecholamines increase arterial pressure through
binding to and activating α-adrenergic receptors on the
smooth muscle cells of the vasculature and can promote
increased cardiac contractility and heart rate through
binding to β-adrenergic receptors of the cardiac muscle
[40]. During sepsis, myocardial depression commonly oc-
curs due to downregulation of β-adrenergic receptors and
related cell signalling pathways [41]. Impaired adrenal
hormone synthesis has also been observed in critically
ill patients and is probably a common complication in
severe sepsis [42, 43]. Interestingly, norepinephrine
levels are decreased in ascorbate-deficient animal
models, particularly in the adrenal glands [44–46]. As-
corbate is also secreted from the adrenal glands as part
of the stress response [47], which could conceivably
Table 1 Summary of studies of ascorbate administration with vasopressor-related endpoints
Study type Study group Intervention Findings Reference
Pre-clinical 24 rats (8/group) Centrally administered ascorbate
(0, 200, 600 nmol)
↑ vasopressin release [62]
↑ antidiuresis
↑ natriuresis
Case report Hospital patient Intravenous ascorbate
(1,500 mg/day)
↑ arterial pressure [35]
↓ heart rate
Normalised central venous
pressure
↓ need for catecholamines
Improved multiple organ
dysfunction
Case report Hospital patient Oral ascorbate (500 mg/day) Resolution of orthostatic
hypotension
[36]
Clinical (retrospective) 33 severely burned patients
(16–17/group)
Intravenous ascorbate
(0, 66 mg/kg/h)
↓ fluid requirement [39]
↓ number of patients requiring
vasopressors
Clinical (randomised, prospective) 37 severely burned patients
(17–18/group)
Intravenous ascorbate
(0, 66 mg/kg/h)
↓ resuscitation fluid volume [38]
↑ diuresis
↓ length of mechanical
ventilation
Clinical (phase I randomised
controlled trial)
24 severe sepsis patients
(8/group)
Intravenous ascorbate
(0, 50, 200 mg/kg/24 h)
↓ systemic organ failure [12]
↑ systolic blood pressurea
↑ mean arterial pressurea
aPreviously unpublished data (R. Natarajan and A. Fowler)
↑ increase, ↓ decrease
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result in adrenal ascorbate depletion under conditions
of sustained stress.
Ascorbate is required for two enzymatic steps along
the catecholamine biosynthetic pathway (Fig. 2). Specif-
ically, ascorbate is a cofactor for the copper-containing
enzyme dopamine β-hydroxylase [48, 49]. This enzyme
utilises oxygen to introduce a hydroxyl group to dopa-
mine to form norepinephrine (Fig. 2). Epinephrine can
then be formed via methyltransferase-catalysed methyla-
tion of the amine group of norepinephrine. Recent re-
search indicates that ascorbate may also facilitate the
rate-limiting step in the synthesis of dopamine via recyc-
ling the enzyme cofactor tetrahydrobiopterin (Fig. 2)
[50]. This cofactor is required by the iron-containing en-
zyme tyrosine hydroxylase which hydroxylates the amino
acid L-tyrosine to form the dopamine precursor
L-DOPA. Some evidence also suggests that ascorbate
enhances the synthesis of tyrosine hydroxylase itself
[50]. Ascorbate has also been shown to enhance both α-
adrenergic and β-adrenergic receptor activity through
binding to the receptor, thereby enhancing its activation
by epinephrine [51, 52].
It is noteworthy that tissues where catecholamines are
synthesised contain the highest levels of ascorbate in the
body (i.e. the brain and adrenal glands) [53], indicating
that vitamin C plays a vital role in these organs. Further-
more, animal models of ascorbate deficiency have shown
significant retention of the vitamin in the brain during
dietary depletion [54–56], supporting the importance of
ascorbate in the central nervous system. Thus, appropri-
ate supplementation of ascorbate in sepsis may support
endogenous synthesis of vasoactive catecholamines, and
possibly also facilitate adrenergic receptor binding.
Ascorbate and vasopressin synthesis
Vasopressin, also known as arginine vasopressin (AVP)
or antidiuretic hormone (ADH), is a peptide hormone
which is synthesised in the hypothalamus as a pre-pro-
hormone and subsequently stored in the posterior pituit-
ary as the mature hormone [57]. It is secreted in response
to decreased blood volume, decreased arterial pressure or
increased plasma osmolality, and interacts with specific
receptors expressed by vascular smooth muscle cells
(AVPR1a) and kidney collecting ducts (AVPR2) to cause
vasoconstriction and water retention [11]. The receptor
AVPR1b (or AVPR3) is expressed in the anterior pituitary,
and stimulation of this receptor by vasopressin en-
hances release of adrenocorticotrophic hormone (ACTH),
thereby acting synergistically with corticotrophin-releasing
hormone (CRH), and resulting in stimulation of cortico-
steroid synthesis in the adrenal cortex in response to stress
[11]. Circulating vasopressin levels increase dramatically
during the initial phase of septic shock, but this is followed
by a significant decline in the latter phase [58, 59]. Patients
in late-phase septic shock have significantly lower levels of
circulating vasopressin compared with patients in cardio-
genic shock, despite similar hypotension [59]. The decline
in circulating vasopressin levels after the onset of septic
shock is due to depletion of pituitary stores and possibly
also impaired vasopressin synthesis [60].
Ascorbate is a cofactor for the copper-containing en-
zyme peptidylglycine α-amidating monooxygenase (PAM)
that is required for the endogenous synthesis of vasopres-
sin [61]. It is of interest to note that the pituitary gland,
where the enzyme PAM is abundantly expressed, has the
highest levels of ascorbate in the body [53]. Thus, it is
conceivable that depletion of the PAM cofactor ascor-
bate during sepsis may contribute to the observed de-
crease in vasopressin biosynthesis [58–60]. Support for
a connection between ascorbate and vasopressin biosyn-
thesis comes from an animal study whereby centrally
Fig. 1 Effect of ascorbate administration on (a) systolic blood pressure
and (b) mean arterial pressure in patients with severe sepsis. Patients
were administered placebo (circle, 5 % dextrose and water, n = 6) or
ascorbate (inverted triangle, 200 mg/kg/24 h, n = 7). The ascorbate
dosage was divided into four equal doses and administered over
30 min every 6 h for 96 h in 50 ml of 5 % dextrose and water [12].
Systolic blood pressure and mean arterial pressure were measured at
the bedside using an arterial line (radial artery)
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administered ascorbate enhanced circulating levels of
vasopressin and induced antidiuresis (Table 1) [62].
Vasopressin is synthesised as a pre-pro-hormone which
undergoes sequential cleavage steps to produce pro-
vasopressin and finally a glycine-extended vasopressin
precursor. The carboxy-terminal glycine residue of the
vasopressin precursor subsequently undergoes post-
translational modification by the ascorbate-dependent
enzyme PAM to generate the active carboxy-amidated
hormone (Fig. 3). The enzyme comprises two domains: a
copper-dependent peptidylglycine α-hydroxylating mono-
oxygenase domain, which converts glycine-extended pep-
tides into a hydroxyglycine intermediate; and a peptidyl
α-hydroxyglycine α-amidating lyase domain, which
converts the hydroxyglycine intermediate into an
amidated product [61]. The carboxy-terminal amine
group of amidated peptides is essential for their bio-
logical activities [63].
Pro-vasopressin and copeptin, which lack the carboxy-
terminal amine present in mature vasopressin, have been
proposed as surrogate measures of the mature amidated
hormone because of their enhanced half-life in circula-
tion [64, 65]. Pro-vasopressin and copeptin levels have
been measured in patients with septic shock and were
shown to be significantly associated with mortality,
higher levels being observed in non-survivors than in
survivors [64, 65]. Circulating copeptin levels are ap-
proximately 10-fold higher than those of vasopressin in
severe sepsis and septic shock [66]; however, it is not
known whether this is simply due to enhanced stability
Fig. 2 Ascorbate-dependent synthesis of the catecholamine vasopressors dopamine, norepinephrine and epinephrine. Ascorbate acts as a cofactor for
the metallo-enzyme dopamine hydroxylase, and also recycles the enzyme cofactor tetrahydrobiopterin. AA ascorbic acid, DHA dehydroascorbic acid,
BH4 tetrahydrobiopterin, BH2 dihydrobiopterin
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of copeptin in circulation and/or decreased synthesis of
mature vasopressin. The assumption that pro-vasopressin/
copeptin levels reflect those of active vasopressin in a
stoichiometric manner would not hold true if post-
translational modification of glycine-extended vaso-
pressin by PAM were affected through limited cofactor
availability. In support of this premise, critically ill pa-
tients with sepsis and systemic inflammatory response
syndrome (SIRS) have a significantly lower ratio of
vasopressin to copeptin than patients after cardiac
surgery [67]. Thus, pro-vasopressin/copeptin should
not be used as a surrogate marker for vasopressin levels
in patients with hypovitaminosis C or hypoxia, both of
which are common in severe sepsis and septic shock.
Conclusions
Ascorbate enhances the synthesis of the vasopressors
norepinephrine and vasopressin by acting as a cofactor
for their respective biosynthetic enzymes. As such, we
hypothesise that administration of high-dose ascorbate
Fig. 3 Ascorbate-dependent synthesis of mature carboxy-terminal amidated vasopressin. Ascorbate is a cofactor for the metallo-enzyme
peptidylglycine α-amidating monooxygenase (PAM). AA ascorbic acid, DHA dehydroascorbic acid
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in conditions of hypovitaminosis C (e.g. severe sepsis
and septic shock) may support the endogenous synthesis
of these vasoactive compounds and thus ameliorate
the need for exogenously administered vasopressors.
Ascorbate-dependent vasopressor synthesis represents
a plausible physiological mechanism whereby ascorbate
could act as an adjuvant therapy for severe sepsis and
septic shock. Whether this mechanism translates into
improved patient outcomes requires testing in well-
designed clinical trials.
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